Its lead candidate has demonstrated clinical benefit in positive Phase 1 and 2 trials, achieved PoC and received FDA green light to enter Phase 3 clinical trials, with first patients to begin treatment in Q2 this year.

Formo is Europe's first cellular agriculture company developing cultivated dairy products - that is dairy which is based on real, animal-free milk proteins produced using precision fermentation.

The PropTech company digitalises and transforms the housing market and establishes housing as a service-oriented product (“Living as a Service”) in the market. Hence, GROPYUS creates high-quality, resource-saving and affordable living spaces with high standards in design, comfort and functionality.

 Its novel technology platform enables the company to deliver products in a much shorter time and to offer policies at a much lower price than any other insurance company.

By combining strategic foresight with deep sector expertise, the firm transforms complex urban challenges into sustainable value. Its integrated approach spans land development, senior living, logistics, and flexible capital solutions, all guided by a strong commitment to ESG and future-ready infrastructure.

Its recombinant protein makes use of the human body’s own defense mechanisms to prevent tissue damage and inflammation driven complications. The investigational medicinal product is being developed to be the driver of this paradigm change as a therapeutic solution in disease areas such as prevention of postoperative inflammatory complications, treatment of pulmonary-arterial hypertension and the prevention of serious disease progression of COVID-19.